retatrutide 2025 trial results This is exciting. 👀 The TRIUMPH-4 for Lilly's investigational medication were released, showing weight loss of up to 71 lbs (~28%) over 68 weeks in the highest-dose group—far beyond Phase III retatrutide study demonstrates

Why is AOD-9604 supplied as a lyophilized powder rather than a pre-mixed solution

Received: Mar 18, 2025

[ Editor's note: After MH went to press, Jelly clarified that he did briefly try weight-loss meds very early on his journey, but stopped after two weeks.] We talked for several hours at intervals over the course of this year about how he was doing it, and how he did it

Growth hormone direct lipolytic effect on visceral adipocytes, which express more GH receptors than subcutaneous fat cells, creates preferential mobilization of the most metabolically dangerous fat

Native oxyntomodulin has significant glucoregulatory effects independent of weight loss in obese humans with and without type 2 diabetes

A pesar de la baja incidencia de estos eventos adversos y de la probabilidad de que los beneficios superen estos riesgos en los individuos con obesidad grave, los mdicos y los pacientes deben ser conscientes de estos efectos secundarios graves